# A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria

> **NCT07316114** · — · RECRUITING · sponsor: **Sanofi** · enrollment: 400 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT07316114
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2027-11-24
- **Final completion:** 2029-11-22
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07316114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07316114, "A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07316114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*